INNATE PHARMA SA

Innate Pharma’s Phase‑1 success with IPH4502 shows a safe, effective Nectin‑4 ADC, offering new hope for patients with urothelial, lung, and head‑and‑neck cancers.

Innate Pharma SA: a Marseille‑based biotech driving cutting‑edge cancer therapies, from antibody pipelines to Lumoxiti, backed by AstraZeneca, BMS and more.

Innate Pharma: Marseille‑based biotech driving cancer therapy advances with Monalizumab, IPH4102, and Lumoxiti, backed by AstraZeneca, BMS, and Sanofi partnerships.

Innate Pharma SA: a Marseille‑based biotech pioneer in antibody oncology, from IPH4102 to Lumoxiti, backed by AstraZeneca and MedImmune partnerships.

Innate Pharma SA, a clinical-stage biotechnology company, is making significant strides in oncology with a robust pipeline of therapeutic antibodies and strategic collaborations, positioning it as a key player in the fight against cancer.